Aprea Therapeutics, Inc. (APRE) NASDAQ
0.76
-0.0022(-0.29%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
0.76
-0.0022(-0.29%)
Currency In USD
Address
535 Boylston St.
Boston, MA 02116
United States of America (the)
Phone
617-463-9385
Website
Sector
Healthcare
Industry
Biotechnology
Employees
8
First IPO Date
October 03, 2019
| Name | Title | Pay | Year Born |
| Oren Gilad | Co-Founder, Chief Executive Officer, President and Director | 598,886 | 1968 |
| John Hamill | Senior Vice President, Chief Financial Officer, Principal Accounting Officer & Secretary | 461,444 | 1964 |
| Lars Abrahmsen | Senior Vice President & Chief Scientific Officer | 0 | 1957 |
| Michel Afargan | Head of Pharmacology Development | 0 | N/A |
| Eugene Kennedy | Chief Medical Advisor | 0 | 1969 |
| Brian Wiley | Senior Vice President of Corporate Development & Strategy | 0 | 1968 |
| Zeev Weiss | Chief Business Advisor | 0 | 1962 |
| Andrea Epstein | Controller | 0 | N/A |
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.